A Study of MSDx Complex 1 as a Marker for Therapy Response in Multiple Sclerosis

Completed

Conditions studied: Relapsing Remitting Multiple Sclerosis

In brief

The purpose of this study is to compare biomarker levels in Multiple Sclerosis (MS) patients before and after beginning Natalizumab.

Key facts

Study ID

NCT01541618

Run by

MSDx, Inc.

People needed

15

Starts

2012-01-01

Expected to finish

2012-07-01

Last updated by the study team

2020-09-02

Who can join

Age: 45 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of clinically definite relapsing remitting MS (RRMS)
• Age 45 years and older
• Willing and able to provide written informed consent
• Patient has high disease activity.
• Patient is about to begin Natalizumab (Tysabri) therapy.

You may not qualify if…

• Any clinically significant disease other than MS that is likely to interfere with the evaluation of CDMS
• Known infectious or hematological disease.
• Unwilling or unable to comply with the requirements of this protocol
• Subject can not have a gadolinium enhanced MRI

Where it is running

• Northwest NeuroSpecialists, PLLC — Tucson, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.